MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference
NEW YORK, Dec. 1, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.
Details on the panel discussion can be found below.
Topic: The Future of Mental Healthcare
Date: Monday, December 6, 2021
Time: 2:30 p.m. ET
A webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December 6, 2021 at 7:00 a.m. ET for those registered for the event.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Media Contact: mindmed@150bond.com
Investor Contact: bmackle@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-present-at-hc-wainwright-2nd-annual-psychedelics-conference-301434349.html
SOURCE Mind Medicine (MindMed) Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/01/c4773.html
DISCLAIMER:
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDARplus.ca for important risk disclosures. It’s your money and your responsibility.